Inclisiran has also been shown to be efficacious in FH patients, with ~40% reduction in LDL-C, highlighting that PCSK9 inhibition is mainly dependent on the up-regulation of normally functioning LDLR and overrides the minor role of clearance of LDL-C via the up-regulation of dysfunctional LDLR [12,13,14]. The gene discussed is LDLR; the disease is familial hyperaldosteronism.